NAD+ Therapy

NAD+ and NADH are two forms of the same molecule. NAD+ accepts electrons during fuel breakdown and becomes NADH; NADH then delivers those electrons to the mitochondrial chain that produces ATP, the cell's energy currency [1]. This constant cycling between oxidized (NAD+) and reduced (NADH) forms is central to energy metabolism.

NAD+ is also consumed — not just cycled — whenever PARPs and sirtuins use it, so levels reflect a continuous balance between production, recycling, and consumption [1-2].

One naming note that matters for anyone researching this topic: much of the historical clinical research on injectable forms of this molecule used NADH (the reduced form), not NAD+. The two are related but distinct compounds, and historical NADH findings cannot simply be read as evidence for modern NAD+ therapy [3-5].

NAD+ injections are the primary NAD+ treatment we currently offer. They are quick in-office intramuscular or subcutaneous injections — typically a matter of minutes — with clinician-guided dosing selected for you.

Most patients purchase treatment in 3-shot packs, because a short series allows your response and tolerance to be assessed over several doses. The dose and frequency can be adjusted as treatment progresses: some patients complete a single pack and reassess, while others continue with additional consecutive packs over several weeks. Where clinically appropriate, Better Off may use a structured series of approximately three visits per week — this is our treatment model for building a series, not a universally established dosing standard, and it has not been proven in outcomes trials to produce any specific result.

Current NAD+ injection options:

• Introductory NAD+ injection (15 mg) — a low-dose first treatment to assess tolerance
• 15 mg 3-pack — introductory series
• 25 mg 3-pack — a common starting dose for many patients
• 50 mg, 75 mg, and 100 mg 3-packs — higher-dose series, selected clinically
• Multi-pack series and maintenance packs — additional consecutive packs or ongoing maintenance after an initial series, as appropriate

Dosing is individualized; your provider reviews your history, goals, and response before recommending a dose or pack size.

1. Start — Clinical screening and an introductory treatment. We review your health history, medications, and goals before your first injection.
2. Choose a 3-pack — A short treatment series, with the dose selected for you.
3. Reassess — We review tolerance, goals, and whether another 3-pack makes sense for you.
4. Continue or maintain — Additional packs or maintenance dosing as appropriate over time.

Injections and IV infusions deliver NAD+ differently:

• Injections are quick, convenient, and suited to frequent dosing over a series — but each dose is comparatively small.
• IV infusion allows substantially larger administered doses in a single visit — but visits take longer, and slower administration is typically used because infusion-related symptoms (flushing, chest pressure, nausea) can occur at faster rates [6-7].

Neither route is automatically "better." The right choice depends on your goals, convenience, and how you respond. Today, Better Off's active NAD+ offering is injections; IV NAD+ remains part of our planned services.

We are preparing to offer IV NAD+ infusion therapy. IV delivery permits substantially larger doses than injections, with visits typically lasting an hour or more depending on the protocol. Slower infusion rates are generally used, because faster administration is associated with transient, rate-related symptoms [6-7].

The current human evidence for IV NAD+ consists of pharmacokinetic and tolerability studies — meaningful data, but limited controlled evidence for wellness outcomes [6-8]. We will not claim more than the evidence supports.

Interested in IV NAD+? Contact us to join the interest list and ask about availability — we'll let you know when it launches and whether it's appropriate for you.

Research has consistently observed that tissue NAD+ levels tend to fall with age. Age-related changes in NAD+ metabolism and oxidative stress have been documented in human tissue [9], and animal research has identified plausible mechanisms — including increased activity of the NAD-consuming enzyme CD38, driven in part by age-associated inflammation [2], and NAD+-dependent disruption of communication between the nucleus and mitochondria [10].

Two cautions matter: much of the mechanistic work is in animal models, and a declining biomarker is not automatically a cause of aging symptoms. That NAD+ changes with age is established; whether restoring it changes the trajectory of aging in humans remains under active investigation [8].

People typically ask about NAD+ because of persistent fatigue, mental slowness, recovery difficulties, or interest in healthy aging. These are real, common concerns — and several of them have multiple possible causes, including sleep, stress, hormonal shifts, metabolic health, and nutrition.

That is why we treat NAD+ as one option to discuss, not an automatic answer: the symptoms people hope to improve are exactly the areas where clinical evidence for NAD+ specifically is still limited [8]. An evaluation first is the honest way to approach it.

NAD+ is not simply an "energy supplement." It is a working part of the chemistry cells use every second to process fuel, transfer electrons, regulate metabolism, and support essential signaling pathways.

One of its best-established roles is in redox metabolism. As carbohydrates, fats, and proteins are broken down, NAD+ accepts electrons and is converted to NADH. NADH then carries those electrons into mitochondrial energy pathways, where they contribute to the reactions that generate ATP — the usable energy currency of the cell. NADH is then oxidized back to NAD+, allowing the cycle to continue [1].

In other words: NAD+ accepts electrons → NADH carries them → mitochondria use that reducing power in energy metabolism → NAD+ is regenerated and used again.

This NAD+/NADH cycling is fundamental to glycolysis, the citric acid cycle, oxidative metabolism, and normal mitochondrial function [1].

NAD+ also has important roles beyond energy transfer. It is consumed as a substrate by several enzyme systems involved in cellular regulation.

Sirtuins are NAD+-dependent enzymes involved in metabolic regulation, mitochondrial homeostasis, gene expression, and cellular responses to stress [1].

PARP enzymes use NAD+ during cellular responses to DNA damage. This does not mean an NAD+ treatment has been proven to "repair DNA," but it does mean NAD+ is directly involved in the biochemical systems cells use when responding to DNA damage [1].

CD38 and related enzymes also consume and regulate NAD+, influencing NAD+ turnover and availability within tissues [2].

Taken together, NAD+ sits at the intersection of several major areas of human physiology:

• cellular energy metabolism
• mitochondrial function
• NAD+/NADH redox balance
• metabolic regulation
• cellular stress responses
• NAD-dependent signaling
• DNA-damage-response pathways

These are established biological functions of NAD+. What researchers are still working out is how strongly changing NAD availability through injections, IV therapy, or oral precursors translates into specific clinical benefits in people.

MEDIA: NAD+ / NADH Cellular Energy Cycle illustration

Interest in NAD+ is not based on a single wellness trend. It comes from decades of research showing that NAD metabolism is tightly connected to energy production, mitochondrial biology, cellular stress signaling, and enzymes that become increasingly relevant in aging and metabolic research [1,9,10].

Human studies also show that NAD-related biology can be altered. Oral precursors such as NR and NMN can increase NAD-related biomarkers [11,12], and intravenous NAD+ has measurable pharmacokinetic and metabolic effects in humans [6].

The important distinction is that showing a biological effect is not the same as proving a specific clinical outcome. The molecular science is strong. Human intervention research is growing. The precise benefits, ideal dosing, treatment schedules, and long-term outcomes of IM and IV NAD+ are still being defined [8].

NAD+ biology itself is well established. The uncertainty is not whether NAD+ matters inside cells; it clearly does.

The open questions are more practical: how much parenteral NAD+ changes tissue NAD availability, which doses and schedules are most meaningful, which patients are most likely to notice a benefit, and which clinical outcomes can be reproduced reliably in controlled human trials [6-8].

That is why Better Off presents NAD+ as an evidence-aware wellness therapy rather than a proven treatment for a specific disease or a guaranteed anti-aging intervention.

Evidence reviewed: August 2026.

These are different ways of trying to raise NAD+ — with different evidence profiles:

• Oral NR (nicotinamide riboside): the most mature human evidence of the three. Controlled trials show it reliably raises blood NAD+ and is well tolerated in healthy middle-aged and older adults [11].
• Oral NMN (nicotinamide mononucleotide): also raises blood NAD+; one rigorous trial showed improved muscle insulin sensitivity in prediabetic women [12]. Note: in late 2022 the FDA excluded NMN from the dietary supplement definition because it was first investigated as a drug — its regulatory status is unsettled [13].
• IV NAD+: delivers the coenzyme directly into the bloodstream, bypassing digestion. A human pharmacokinetic pilot confirmed that a slow 6-hour infusion changes the circulating NAD+ metabolome [6], and a recent retrospective pilot found real-world infusions were tolerated [7]. IV NAD+ has far less clinical-outcome evidence than oral NR — no one has yet shown infusions produce superior clinical results [7-8].

A higher blood level is not automatically a better clinical outcome. Which approach makes sense depends on your goals, health context, and what the evidence can honestly support.

Long before modern NAD+ interest, clinicians studied injectable NADH — the reduced form of the molecule — most notably in Parkinson's disease. In the late 1980s and 1990s, Birkmayer and colleagues reported that NADH stimulated endogenous L-dopa biosynthesis and described clinical observations in parkinsonian patients [3-5].

This history matters for two reasons. First, it shows genuine clinical interest in parenteral NAD-related therapies spanning decades, across neurological and other conditions. Second, it requires careful reading: those studies used NADH, not NAD+, and they were largely observational and dated by modern trial standards. They do not constitute evidence that modern NAD+ injections produce the same effects. We include them for completeness and scientific honesty, not as support for any specific outcome claim.

The human data to date describe mostly mild, transient, route-related effects. For infusions, faster rates are associated with flushing, chest pressure, warmth, nausea, or headache that typically ease when the drip is slowed [6-7]. For injections, local injection-site discomfort is the most common consideration, as with any injection.

Large-scale safety data for repeated NAD+ administration do not yet exist — one reason we screen before treatment and administer under clinical supervision [7-8].

Evidence disclaimer: NAD+ injections and IV NAD+ are elective wellness treatments with limited clinical-outcome evidence. They have not been proven to reverse aging, extend lifespan, treat cognitive disease, treat Parkinson's disease or dementia, cure fatigue, detoxify the body, improve immunity, or prevent disease.

NAD+ therapy is not appropriate for everyone. Before treatment, we review your medical history, medications, and goals, and screen for conditions where caution is warranted. We also consider whether your symptoms might have other, more treatable causes: sleep disorders, thyroid or hormonal changes, nutritional deficiencies, depression, or medication effects.

If NAD+ isn't the right first step for you, we'll say so and point you toward what is.

Many clinics market NAD+ as a proven anti-aging treatment. We don't. Our position is straightforward:

• NAD+ biology is genuinely well-established science [1-2].
• Age-related NAD changes are real and being seriously studied [2,8-10].
• NAD+ injections offer a convenient, clinician-guided way to begin; IV delivery is coming for those who want larger-dose options.
• Clinical-outcome evidence for NAD+ administration remains early [6-8] — so we counsel honestly about what is and isn't known, screen before treating, and never pressure you into a series you don't need.

You should never have to choose between being sold to and being left to figure it out alone. Our job is to give you the real picture and help you decide.